130 related articles for article (PubMed ID: 9127635)
1. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
Lissoni P; Pittalis S; Rovelli F; Vigorè L; Roselli MG; Brivio F
J Biol Regul Homeost Agents; 1995; 9(2):63-6. PubMed ID: 9127635
[TBL] [Abstract][Full Text] [Related]
2. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
3. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
[TBL] [Abstract][Full Text] [Related]
4. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
[TBL] [Abstract][Full Text] [Related]
5. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
Lissoni P; Barni S; Ardizzoia A; Brivio F; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1992; 6(4):132-6. PubMed ID: 1296454
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
7. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
Lissoni P; Tisi E; Brivio F; Ardizzoia A; Crispino S; Barni S; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
[TBL] [Abstract][Full Text] [Related]
8. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
Lissoni P; Ardizzoia A; Tisi E; Rossini F; Barni S; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1993; 7(1):34-6. PubMed ID: 8346714
[TBL] [Abstract][Full Text] [Related]
9. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Tancini G
J Biol Regul Homeost Agents; 1995; 9(2):52-4. PubMed ID: 9127633
[TBL] [Abstract][Full Text] [Related]
11. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
Lissoni P; Brivio F; Barni S; Tancini G; Cattaneo G; Archili C; Conti A; Maestroni GJ
Anticancer Res; 1990; 10(6):1759-61. PubMed ID: 2285255
[TBL] [Abstract][Full Text] [Related]
12. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
Lissoni P; Barni S; Tancini G; Brivio F; Tisi E; Zubelewicz B; Braczkowski R
J Biol Regul Homeost Agents; 1994; 8(4):126-9. PubMed ID: 7660855
[TBL] [Abstract][Full Text] [Related]
13. Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin.
Bregani ER; Lissoni P; Rossini F; Barni S; Tancini G; Brivio F; Conti A; Maestroni GJ
Recenti Prog Med; 1995 Jun; 86(6):231-3. PubMed ID: 7624582
[TBL] [Abstract][Full Text] [Related]
14. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
Lissoni P
Ann N Y Acad Sci; 2000; 917():560-7. PubMed ID: 11268384
[TBL] [Abstract][Full Text] [Related]
15. Melatonin as a new possible anti-inflammatory agent.
Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
[TBL] [Abstract][Full Text] [Related]
16. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
Lissoni P; Rovelli F; Brivio F; Fumagalli L; Brera G
In Vivo; 2008; 22(3):397-400. PubMed ID: 18610754
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cytokine production from TH2-lymphocytes and monocytes by the pineal neurohormone melatonin.
Lissoni P; Pittalis S; Rovelli F; Roselli M; Ardizzoia A
Oncol Rep; 1996 May; 3(3):541-3. PubMed ID: 21594408
[TBL] [Abstract][Full Text] [Related]
18. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
Brackowski R; Zubelewicz B; Romanowski W; Lissoni P; Barni S; Tancini G; Maestroni GJ
J Biol Regul Homeost Agents; 1994; 8(3):77-80. PubMed ID: 7754792
[TBL] [Abstract][Full Text] [Related]
19. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors.
Lissoni P; Rovelli F; Tisi E; Brivio F; Ardizzoia A; Barni S; Tancini G; Saudelli M; Cesana E; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(4):146-9. PubMed ID: 8844339
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
Lissoni P; Barni S; Ardizzoia A; Olivini G; Brivio F; Tisi E; Tancini G; Characiejus D; Kothari L
J Biol Regul Homeost Agents; 1993; 7(4):121-5. PubMed ID: 8023699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
